Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA; LV Prasad Eye Institute, Hyderabad, India.
Ocul Surf. 2021 Jan;19:128-132. doi: 10.1016/j.jtos.2020.05.003. Epub 2020 May 20.
To evaluate the effect of systemic cyclosporine (CsA) on ocular disease in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients.
In this retrospective, comparative cohort study at a single center, patients with a diagnosis of SJS/TEN and with at least 3 months of follow up were divided into two groups: those who received systemic CsA and those who did not receive systemic CsA. Best-corrected visual acuity (BCVA) and chronic ocular surface complications score (COCS) at final follow-up were compared between the two groups.
The median age and follow-up period of patients was 29 years (range, 1.5-71 years) and 16.8 months (range, 3.67-91.58 months), respectively. BCVA, COCS, meibomian gland dysfunction, limbal stem cell deficiency, and the need for mucous membrane grafting and scleral lenses were not significantly different between patients who received systemic CsA as compared to patients who did not receive systemic CsA.
In this small cohort of patients with SJS/TEN, we could identify no association between the use of systemic CsA as a component of their initial therapy and chronic ocular complications.
评估全身性环孢素（CsA）对史蒂文斯-约翰逊综合征（SJS）和中毒性表皮坏死松解症（TEN）患者眼部疾病的影响。
在单中心回顾性对比队列研究中，将诊断为 SJS/TEN 且随访时间至少 3 个月的患者分为两组：接受全身性 CsA 治疗的患者和未接受全身性 CsA 治疗的患者。比较两组患者最终随访时的最佳矫正视力（BCVA）和慢性眼表并发症评分（COCS）。
患者的中位年龄和随访时间分别为 29 岁（范围：1.5-71 岁）和 16.8 个月（范围：3.67-91.58 个月）。与未接受全身性 CsA 治疗的患者相比，接受全身性 CsA 治疗的患者的 BCVA、COCS、睑板腺功能障碍、角膜缘干细胞缺乏症以及需要进行黏膜移植和巩膜镜片的情况并无显著差异。
在本项 SJS/TEN 小患者队列研究中，我们未发现全身性 CsA 作为初始治疗的一部分与慢性眼部并发症之间存在关联。
